香港股市 已收市
  • 恒指

    18,597.23
    +392.55 (+2.16%)
     
  • 國指

    6,374.44
    +137.72 (+2.21%)
     
  • 上證綜指

    3,151.34
    +1.59 (+0.05%)
     
  • 道指

    33,731.86
    -120.67 (-0.36%)
     
  • 標普 500

    3,955.27
    -2.36 (-0.06%)
     
  • 納指

    11,031.39
    +47.61 (+0.43%)
     
  • Vix指數

    22.14
    +0.25 (+1.14%)
     
  • 富時100

    7,580.79
    +68.79 (+0.92%)
     
  • 紐約期油

    80.54
    +2.34 (+2.99%)
     
  • 金價

    1,769.60
    +5.90 (+0.33%)
     
  • 美元

    7.7983
    -0.0117 (-0.15%)
     
  • 人民幣

    0.9071
    -0.0090 (-0.98%)
     
  • 日圓

    0.0557
    -0.0004 (-0.70%)
     
  • 歐元

    8.0825
    +0.0205 (+0.25%)
     
  • Bitcoin

    16,834.22
    +454.93 (+2.78%)
     
  • CMC Crypto 200

    399.57
    -1.13 (-0.28%)
     

Labcorp To Spin Off Its Clinical Trial Business, Posts Mixed Q2 Earnings

  • Laboratory Corp of America Holdings (NYSE: LHplans to spin off its unit focused on the clinical development business. Wall Street Journal was the first to report the news.

  • The clinical drug trial business operates as a Contract Research Organization, providing Phase I-IV clinical trial management, market access, and technology solutions to pharmaceutical and biotechnology organizations.

  • According to WSJ, the move will create a new stand-alone company in the fast-growing contract-research sector.

  • Labcorp plans to retain the parts of the drug-development business that focus on early-stage development and central laboratory work, given that they require similar resources to its diagnostics operation, WSJ reported.

  • The spun-off business delivered total revenue of $3.0 billion in the 12 months ending June. It grew 8% on a CAGR basis from Q2 2019 to Q2 2022.

  • The Clinical Development business is expected to deliver high-single-digit revenue growth in the future.

  • Labcorp is targeting completion of the planned spin-off in 2H of 2023.

  • The company reported Q2 sales of $3.70 billion, missing the consensus of $3.75 billion, down 3.7% Y/Y due to lower COVID-19 PCR and antibody testing.

  • Q2 adjusted EPS reached $4.96 versus $6.13 last year, beating the consensus of $4.70.

  • Guidance: Labcorp expects FY22 EPS of $19.00 - $21.25, compared to the prior guidance of $18.25 - $21.00 and the consensus of $19.70.

  • Price Action: LH shares are up 0.61% at $251.00 during the premarket session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.